Every biotech chief has something to say about overcoming the burdens of long and expensive journeys to bring new drugs to market.
Medidata Solutions ($MDSO) has nailed down more business from a major pharma outfit. Purdue Pharma, known for making the pain drug OxyContin, has inked a multiyear deal with Medidata, expanding use of Medidata's software for clinical trials.
BioClinica told investors that it won't be issuing annual guidance for 2013. That's because the provider of clinical trials software and core lab imaging is being bought in a $123 million private equity deal.
The New York-based private equity player JLL Partners has struck a deal to buy the growing eClinical outfit BioClinica for $7.25 per share or about $123 million, paying a 23.2% premium on the average closing price of the company's stock for the past 90 days.
Behind the huge and scary numbers that accompany the costs of drug development, there are various holes and dysfunctional practices in the process of bringing a new drug to market.
The CRO giant Parexel International ($PRXL) announced a changing of the guard at its Perceptive Informatics unit, which provides electronic clinical trials (eClinical) software. Healthcare software veteran Xavier Flinois is taking over for Steve Kent as president of Perceptive, the parent company said this morning.
The 800-pound gorilla in pharma companies' oft-criticized R&D budgets is the cost of large clinical trials. In the race to provide ways to trim the big expense, CluePoints has debuted with a software and service to identify potential errors in clinical trials data and derisk regulatory submissions.
Epocrates has caught the attention of pharma players with trendy mobile apps for physicians that let them look up info on prescription meds. AthenaHealth, an electronic health records outfit, has bet on the app provider in a $293 million buyout of the company.
A consortium is targeting the discovery of a new primary endpoint for multiple sclerosis trials by analyzing data from current studies. The alliance hopes that by sifting through the wealth of data generated by MS trials, they can find a clinician-reported outcome measure of disability.
In an article in Life Science Leader , Pfizer's Craig Lipset talked about how the company's virtual clinical trial rolled out many new tech tools at once to trial the overall bladder drug Detrol, with some setbacks along the way.